BioLife Solutions, Inc. (NASDAQ:BLFS) Given Average Recommendation of “Buy” by Analysts

Shares of BioLife Solutions, Inc. (NASDAQ:BLFS) have been given a consensus recommendation of “Buy” by the six analysts that are currently covering the company, MarketBeat Ratings reports. Six research analysts have rated the stock with a buy rating. The average 12-month target price among brokers that have updated their coverage on the stock in the last year is $31.17.

A number of research firms have weighed in on BLFS. HC Wainwright reiterated a “buy” rating and issued a $30.00 price target on shares of BioLife Solutions in a research report on Tuesday, May 13th. Wall Street Zen cut shares of BioLife Solutions from a “hold” rating to a “sell” rating in a research report on Wednesday, May 21st.

Insider Activity

In related news, EVP Aby J. Mathew sold 10,589 shares of the business’s stock in a transaction on Tuesday, April 1st. The shares were sold at an average price of $22.66, for a total value of $239,946.74. Following the sale, the executive vice president now owns 309,576 shares in the company, valued at approximately $7,014,992.16. The trade was a 3.31% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, major shareholder Casdin Partners Master Fund, L sold 1,000,000 shares of the business’s stock in a transaction on Tuesday, June 10th. The stock was sold at an average price of $23.80, for a total transaction of $23,800,000.00. Following the completion of the sale, the insider now owns 7,707,165 shares in the company, valued at $183,430,527. This represents a 11.48% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 1,057,674 shares of company stock worth $25,104,065 over the last quarter. Insiders own 2.20% of the company’s stock.

Institutional Investors Weigh In On BioLife Solutions

Large investors have recently bought and sold shares of the business. D.A. Davidson & CO. raised its holdings in BioLife Solutions by 1.3% in the fourth quarter. D.A. Davidson & CO. now owns 41,179 shares of the medical equipment provider’s stock worth $1,069,000 after purchasing an additional 519 shares in the last quarter. Sei Investments Co. increased its holdings in shares of BioLife Solutions by 0.5% during the first quarter. Sei Investments Co. now owns 117,999 shares of the medical equipment provider’s stock valued at $2,695,000 after acquiring an additional 547 shares in the last quarter. Rhumbline Advisers increased its holdings in shares of BioLife Solutions by 0.7% during the first quarter. Rhumbline Advisers now owns 83,227 shares of the medical equipment provider’s stock valued at $1,901,000 after acquiring an additional 566 shares in the last quarter. GAMMA Investing LLC increased its holdings in shares of BioLife Solutions by 18.6% during the first quarter. GAMMA Investing LLC now owns 4,223 shares of the medical equipment provider’s stock valued at $96,000 after acquiring an additional 663 shares in the last quarter. Finally, 1620 Investment Advisors Inc. increased its holdings in shares of BioLife Solutions by 41.7% during the fourth quarter. 1620 Investment Advisors Inc. now owns 2,295 shares of the medical equipment provider’s stock valued at $60,000 after acquiring an additional 675 shares in the last quarter. Institutional investors own 93.24% of the company’s stock.

BioLife Solutions Stock Performance

BLFS opened at $22.29 on Tuesday. The firm has a market cap of $1.06 billion, a P/E ratio of -21.03 and a beta of 1.82. BioLife Solutions has a 1-year low of $18.70 and a 1-year high of $29.55. The company has a 50 day simple moving average of $22.75 and a two-hundred day simple moving average of $24.90. The company has a debt-to-equity ratio of 0.03, a current ratio of 2.78 and a quick ratio of 1.78.

BioLife Solutions (NASDAQ:BLFS) last posted its quarterly earnings results on Thursday, May 8th. The medical equipment provider reported $0.04 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.03) by $0.07. The business had revenue of $23.94 million during the quarter, compared to analyst estimates of $22.22 million. BioLife Solutions had a negative net margin of 38.98% and a negative return on equity of 6.61%. Equities analysts forecast that BioLife Solutions will post -0.3 earnings per share for the current fiscal year.

BioLife Solutions Company Profile

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.